Clinical trials: Atopic Disease
- Condition Atopic Disease
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate…
- Trial name
- NCT05859724
- Testing
- NM26-2198
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Yellow Jersey Therapeutics AG
Atopic Dermatitis
Effects of Lactobacillus Reuteri Plus Vitamin D3 in Children With Atopic Dermatitis
The purpose of this study is to evaluate in a randomized, double-blinded, controlled trial, whether a new food supplement containing Lactobacillus reuteri DSM 17938 and vitamin D3 (Reuterin® D3) may improve the SCORAD in…
- Trial name
- NCT02945683
- Testing
- Reuterin D3
- Where
- Italy
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Noos S.r.l.
Dermatitis, Atopic
Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients
The aim of the study is to evaluate the beneficial effect of a probiotic preparation with an antiinflammatory and modulating activity on immunological processes, with positive results on different inflammatory and atopic…
- Trial name
- NCT02585986
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Atopic Dermatitis
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
- Trial name
- NCT00316602
- Testing
- IMVAMUNE
- Where
- 22 sites in United States, Mexico
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Safety Issues
A Phase I Clinical Study of Hemay808
This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028.
- Trial name
- NCT04100642
- Testing
- Hemay808
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
A First-in-Human Study of QY211 Gel in Adult Subjects
This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of…
- Trial name
- NCT05843422
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
A First-in-Human Study of CEE321 in Adult Subjects
Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
- Trial name
- NCT04612062
- Testing
- CEE321
- Where
- 3 sites in United States, Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes including gene expression, protein degradation, and multiple cellular stress responses.
- Trial name
- NCT05215808
- Testing
- RBN-3143
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ribon Therapeutics, Inc.
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Dermatitis, Atopic
Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream
Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a form of eczema).The purpose of this clinical…
- Trial name
- NCT01098734
- Testing
- WBI-1001
- Where
- 5 sites in Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Atopic Dermatitis, Psoriasis
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
- Trial name
- NCT05718921
- Testing
- YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Atopic Immunoglobulin E-Mediated Allergic Disorder
A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
The primary objective of this study is to assess the safety and tolerability of STMC-103H compared to placebo in allergic subjects who are otherwise healthy.
- Trial name
- NCT03819881
- Testing
- STMC-103H
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.
Atopic Dermatitis
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs.
- Trial name
- NCT04192513
- Testing
- J. lividum
- Where
- Dominican Republic
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Atopic Dermatitis
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a…
- Trial name
- NCT07920783
- Testing
- GLR2053 Tablets
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Healthy, Asthma
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent…
- Trial name
- NCT02243189
- Testing
- JNJ-43260295, Nasal Allergen Challenge
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Dermatitis, Atopic
In-Use Test With a Cosmetic Product
The aim of the study is to evaluate the tolerance of the product WO 4260 by a dermatologist. Additional objectives of this clinical in-use study are to evaluate the cosmetic features and acceptance of the product by means of a…
- Trial name
- NCT03252730
- Testing
- WO 4260 Cosmetic Product for Topical Use
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Atopic Dermatitis
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth.
- Trial name
- NCT07172321
- Testing
- PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Clinical Study of HRS-8797 in Healthy Participants
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
- Trial name
- NCT07698756
- Testing
- HRS-8797
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC